FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520170146> ?p ?o ?g. }

• W2520170146 endingPage "e4890" @default.
• W2520170146 startingPage "e4890" @default.
• W2520170146 abstract "Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months. ABC/3TC/NVP was compared to ABC/3TC with either ritonavir-boosted darunavir (DRV/r) or ritonavir-boosted atazanavir (ATV/r), unboosted ATV, or tenofovir/emtricitabine (TDF/FTC) with either one of the following: ATV/r, unboosted ATV, DRV/r, efavirenz (EFV), or NVP, in the French prospective multicenter Dat’AIDS cohort. The study enrolled 16,511 patients treated with following ARV regimens: ABC/3TC/NVP (n = 1089), TDF/FTC/NVP (n = 1542), ABC/3TC/DRV/r (n = 1065), ABC/3TC/ATV/r (n = 1847), ABC/3TC/ATV (n = 563), TDF/FTC/ATV/r (n = 3519), TDF/FTC/DRV/r (n = 2767), TDF/FTC/ATV (n = 419), and TDF/FTC/EFV (n = 3700). Mean follow-up was 36 ± 24 months. Patients treated with ABC/3TC/NVP received this regimen as a switch regimen in 97% of cases. By multivariable analysis, the risk of treatment discontinuation due to VF was similar between ABC/3TC/NVP and other ARV regimens, except for TDF/FTC/ATV and ABC/3TC/ATV, which were associated with a higher risk of treatment interruption due to VF (hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.29–3.06 and HR 2.19; 95% CI 1.51–3.18, respectively). Treatment discontinuation due to ADR was lowest with the ABC/3TC/NVP regimen. Other ARV regimens were associated with a 1.80- to 3.19-fold increase in the risk of treatment discontinuation due to ADR (P < 0.0001 for all comparisons). ABC/3TC/NVP as a simplification regimen is a long-term effective regimen with lower discontinuation due to long-term toxicity compared with other standard ARV regimens." @default.
• W2520170146 created "2016-09-23" @default.
• W2520170146 creator A5042023998 @default.
• W2520170146 creator A5046960794 @default.
• W2520170146 creator A5054867866 @default.
• W2520170146 creator A5055718888 @default.
• W2520170146 creator A5056512475 @default.
• W2520170146 creator A5056979197 @default.
• W2520170146 creator A5057185222 @default.
• W2520170146 creator A5063316888 @default.
• W2520170146 creator A5081353121 @default.
• W2520170146 creator A5086090445 @default.
• W2520170146 creator A5089539215 @default.
• W2520170146 date "2016-09-01" @default.
• W2520170146 modified "2023-10-17" @default.
• W2520170146 title "Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study" @default.
• W2520170146 cites W1486786706 @default.
• W2520170146 cites W1933052783 @default.
• W2520170146 cites W1964841369 @default.
• W2520170146 cites W1970937993 @default.
• W2520170146 cites W1978364917 @default.
• W2520170146 cites W2008258552 @default.
• W2520170146 cites W2018110380 @default.
• W2520170146 cites W2027613075 @default.
• W2520170146 cites W2032619697 @default.
• W2520170146 cites W2039691644 @default.
• W2520170146 cites W2068866500 @default.
• W2520170146 cites W2106473738 @default.
• W2520170146 cites W2125429450 @default.
• W2520170146 cites W2128761506 @default.
• W2520170146 cites W2130044431 @default.
• W2520170146 cites W2149717057 @default.
• W2520170146 cites W2166746687 @default.
• W2520170146 cites W2169767760 @default.
• W2520170146 cites W2216284730 @default.
• W2520170146 cites W2231604878 @default.
• W2520170146 cites W2312804821 @default.
• W2520170146 cites W2322202895 @default.
• W2520170146 cites W4240243247 @default.
• W2520170146 cites W90256038 @default.
• W2520170146 doi "https://doi.org/10.1097/md.0000000000004890" @default.
• W2520170146 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5402604" @default.
• W2520170146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27631261" @default.
• W2520170146 hasPublicationYear "2016" @default.
• W2520170146 type Work @default.
• W2520170146 sameAs 2520170146 @default.
• W2520170146 citedByCount "9" @default.
• W2520170146 countsByYear W25201701462018 @default.
• W2520170146 countsByYear W25201701462019 @default.
• W2520170146 countsByYear W25201701462020 @default.
• W2520170146 countsByYear W25201701462021 @default.
• W2520170146 countsByYear W25201701462022 @default.
• W2520170146 crossrefType "journal-article" @default.
• W2520170146 hasAuthorship W2520170146A5042023998 @default.
• W2520170146 hasAuthorship W2520170146A5046960794 @default.
• W2520170146 hasAuthorship W2520170146A5054867866 @default.
• W2520170146 hasAuthorship W2520170146A5055718888 @default.
• W2520170146 hasAuthorship W2520170146A5056512475 @default.
• W2520170146 hasAuthorship W2520170146A5056979197 @default.
• W2520170146 hasAuthorship W2520170146A5057185222 @default.
• W2520170146 hasAuthorship W2520170146A5063316888 @default.
• W2520170146 hasAuthorship W2520170146A5081353121 @default.
• W2520170146 hasAuthorship W2520170146A5086090445 @default.
• W2520170146 hasAuthorship W2520170146A5089539215 @default.
• W2520170146 hasBestOaLocation W25201701461 @default.
• W2520170146 hasConcept C126322002 @default.
• W2520170146 hasConcept C142462285 @default.
• W2520170146 hasConcept C159047783 @default.
• W2520170146 hasConcept C207103383 @default.
• W2520170146 hasConcept C2522874641 @default.
• W2520170146 hasConcept C2777869810 @default.
• W2520170146 hasConcept C2778715236 @default.
• W2520170146 hasConcept C2779130552 @default.
• W2520170146 hasConcept C2779298103 @default.
• W2520170146 hasConcept C2779465607 @default.
• W2520170146 hasConcept C2779778239 @default.
• W2520170146 hasConcept C2780593183 @default.
• W2520170146 hasConcept C2781413609 @default.
• W2520170146 hasConcept C2781432083 @default.
• W2520170146 hasConcept C2993143319 @default.
• W2520170146 hasConcept C3013748606 @default.
• W2520170146 hasConcept C44249647 @default.
• W2520170146 hasConcept C71924100 @default.
• W2520170146 hasConcept C98274493 @default.
• W2520170146 hasConceptScore W2520170146C126322002 @default.
• W2520170146 hasConceptScore W2520170146C142462285 @default.
• W2520170146 hasConceptScore W2520170146C159047783 @default.
• W2520170146 hasConceptScore W2520170146C207103383 @default.
• W2520170146 hasConceptScore W2520170146C2522874641 @default.
• W2520170146 hasConceptScore W2520170146C2777869810 @default.
• W2520170146 hasConceptScore W2520170146C2778715236 @default.
• W2520170146 hasConceptScore W2520170146C2779130552 @default.
• W2520170146 hasConceptScore W2520170146C2779298103 @default.
• W2520170146 hasConceptScore W2520170146C2779465607 @default.
• W2520170146 hasConceptScore W2520170146C2779778239 @default.
• W2520170146 hasConceptScore W2520170146C2780593183 @default.
• W2520170146 hasConceptScore W2520170146C2781413609 @default.
• W2520170146 hasConceptScore W2520170146C2781432083 @default.

• next